KR20160020543A - 씨. 디피실에 대해서 면역화시키는 조성물 및 방법 - Google Patents

씨. 디피실에 대해서 면역화시키는 조성물 및 방법 Download PDF

Info

Publication number
KR20160020543A
KR20160020543A KR1020167001130A KR20167001130A KR20160020543A KR 20160020543 A KR20160020543 A KR 20160020543A KR 1020167001130 A KR1020167001130 A KR 1020167001130A KR 20167001130 A KR20167001130 A KR 20167001130A KR 20160020543 A KR20160020543 A KR 20160020543A
Authority
KR
South Korea
Prior art keywords
days
administration
day
toxin
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167001130A
Other languages
English (en)
Korean (ko)
Inventor
패트리샤 피에트로본
지나마리 포글리아
브륀 가이 드
산자이 구루나탄
Original Assignee
사노피 파스퇴르 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160020543(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피 파스퇴르 인코포레이티드 filed Critical 사노피 파스퇴르 인코포레이티드
Publication of KR20160020543A publication Critical patent/KR20160020543A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167001130A 2013-06-14 2014-06-13 씨. 디피실에 대해서 면역화시키는 조성물 및 방법 Ceased KR20160020543A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
US61/835,246 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (1)

Publication Number Publication Date
KR20160020543A true KR20160020543A (ko) 2016-02-23

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167001130A Ceased KR20160020543A (ko) 2013-06-14 2014-06-13 씨. 디피실에 대해서 면역화시키는 조성물 및 방법

Country Status (12)

Country Link
US (4) US9730994B2 (enExample)
EP (1) EP3007724B1 (enExample)
JP (1) JP6691477B2 (enExample)
KR (1) KR20160020543A (enExample)
CN (1) CN105611942A (enExample)
AU (1) AU2014277981B2 (enExample)
BR (1) BR112015031088A2 (enExample)
CA (1) CA2915279A1 (enExample)
MX (1) MX2015017257A (enExample)
SG (1) SG11201510166YA (enExample)
TW (1) TWI648063B (enExample)
WO (1) WO2014201346A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2020003756A (es) * 2017-09-28 2020-07-29 Pfizer Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
HK1213917A1 (zh) 2013-03-15 2016-07-15 Sanofi Pasteur, Inc. 類霉素、組合物及相關方法
KR20150133770A (ko) * 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile

Also Published As

Publication number Publication date
TWI648063B (zh) 2019-01-21
US20170304423A1 (en) 2017-10-26
US20210145956A1 (en) 2021-05-20
WO2014201346A1 (en) 2014-12-18
EP3007724A1 (en) 2016-04-20
JP6691477B2 (ja) 2020-04-28
BR112015031088A2 (pt) 2017-07-25
US20200113991A1 (en) 2020-04-16
US11419930B2 (en) 2022-08-23
US9730994B2 (en) 2017-08-15
US20160120968A1 (en) 2016-05-05
TW201536314A (zh) 2015-10-01
JP2016521754A (ja) 2016-07-25
MX2015017257A (es) 2016-11-11
CN105611942A (zh) 2016-05-25
CA2915279A1 (en) 2014-12-18
SG11201510166YA (en) 2016-01-28
AU2014277981A1 (en) 2016-01-07
AU2014277981B2 (en) 2019-06-20
EP3007724B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
US11419930B2 (en) Compositions and methods for immunizing against C. difficile
US20230062987A1 (en) Methods and compositions for immune protection against extra-intestinal pathogenic e. coli
Enioutina et al. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity
RU2623174C2 (ru) Вакцины и композиции против streptococcus pneumoniae
CN102548572A (zh) 抗肺炎链球菌的疫苗和组合物
RU2559782C2 (ru) Набор для детекции спор, происходящих из микобактерий
CN117982638B (zh) 免疫佐剂联合pd-1抗体药物在治疗胰腺癌中的应用
CN111281973A (zh) 含有trpv2激动剂的疫苗佐剂及其用途
US20240189410A1 (en) Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2026067038A1 (zh) 一种用于预防或治疗破伤风的联合疫苗
CN117586370A (zh) 强毒性淀粉样蛋白寡聚体及其用途
WO2018006939A1 (en) Inactivated tuberculosis vaccine
JP2021503509A (ja) 哺乳動物における趾皮膚炎に使用されるワクチン組成物
CN110507819A (zh) 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
TW202612726A (zh) 誘發針對困難梭狀芽孢桿菌的免疫反應之免疫原性組成物和方法
CN121609768A (zh) 一种肺炎克雷伯菌截短的外膜蛋白及其用途
US20190008941A1 (en) Combined therapy and prophylaxis for genital tract infections
US20180071379A1 (en) Combined therapy and prophylaxis for genital tract infections
Smith et al. Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect
JP2021504478A (ja) 生殖管感染症に対する併用療法と予防
Sanders Investigation of the potential of PorA and FetA as meningococcal vaccine components
US20080226661A1 (en) Phage Screening Assay
HK1172254A (en) Vaccines and compositions against streptococcus pneumoniae

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)